JP2024532477A5 - - Google Patents
Info
- Publication number
- JP2024532477A5 JP2024532477A5 JP2024513896A JP2024513896A JP2024532477A5 JP 2024532477 A5 JP2024532477 A5 JP 2024532477A5 JP 2024513896 A JP2024513896 A JP 2024513896A JP 2024513896 A JP2024513896 A JP 2024513896A JP 2024532477 A5 JP2024532477 A5 JP 2024532477A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- antisense oligonucleotide
- nucleic acid
- oligonucleotide comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240226P | 2021-09-02 | 2021-09-02 | |
| US63/240,226 | 2021-09-02 | ||
| US202263315669P | 2022-03-02 | 2022-03-02 | |
| US63/315,669 | 2022-03-02 | ||
| PCT/US2022/042393 WO2023034537A1 (en) | 2021-09-02 | 2022-09-01 | Compositions and methods for modulating kras expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532477A JP2024532477A (ja) | 2024-09-05 |
| JP2024532477A5 true JP2024532477A5 (https=) | 2025-09-08 |
Family
ID=85411569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513896A Pending JP2024532477A (ja) | 2021-09-02 | 2022-09-01 | Ｋｒａｓ発現を調節するための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240392293A1 (https=) |
| EP (1) | EP4395901A4 (https=) |
| JP (1) | JP2024532477A (https=) |
| KR (1) | KR20240051272A (https=) |
| WO (1) | WO2023034537A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119855910A (zh) | 2022-07-06 | 2025-04-18 | 美国微哲默理有限责任公司 | 用于治疗胰腺癌的组合物和方法 |
| EP4652279A2 (en) * | 2023-01-18 | 2025-11-26 | Molecular Axiom, LLC | Compositions for modulating kras expression and uses thereof |
| CN119639745B (zh) * | 2024-12-12 | 2025-11-25 | 制能(北京)生物科技有限公司 | 一种靶向kras基因的反义核酸及其药物制剂和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| JP2010538678A (ja) * | 2007-09-18 | 2010-12-16 | イントラドイグム コーポレーション | Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法 |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| EA201492004A1 (ru) * | 2012-05-02 | 2015-08-31 | Новартис Аг | Органические композиции для лечения kras-ассоциированных заболеваний |
| CN108513588A (zh) * | 2015-09-24 | 2018-09-07 | Ionis制药公司 | Kras表达的调节剂 |
| US11180759B2 (en) * | 2016-01-19 | 2021-11-23 | The University Of North Carolina At Chapel Hill | Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS |
| KR101997116B1 (ko) * | 2016-10-14 | 2019-07-05 | 연세대학교 산학협력단 | Kras 유전자에 상보적인 가이드 rna 및 이의 용도 |
| WO2018146316A1 (en) * | 2017-02-13 | 2018-08-16 | Astrazeneca Ab | Combination of a mapk pathway inhibitor and an antisense compound targeted to kras |
| US11512315B2 (en) * | 2018-02-12 | 2022-11-29 | Codiak Biosciences, Inc. | Methods and compositions for macrophage polarization |
| CA3147701A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
| JP7427227B2 (ja) * | 2020-01-21 | 2024-02-05 | 学校法人産業医科大学 | 腫瘍細胞の生存を低下させるｋｒａｓアンチセンスオリゴヌクレオチド及びその用途 |
-
2022
- 2022-09-01 KR KR1020247011068A patent/KR20240051272A/ko active Pending
- 2022-09-01 JP JP2024513896A patent/JP2024532477A/ja active Pending
- 2022-09-01 WO PCT/US2022/042393 patent/WO2023034537A1/en not_active Ceased
- 2022-09-01 US US18/688,568 patent/US20240392293A1/en active Pending
- 2022-09-01 EP EP22865580.9A patent/EP4395901A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024532477A5 (https=) | ||
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| RU2689548C2 (ru) | Лечение рака | |
| CN108271351B (zh) | 用于调节血管紧张素原表达的化合物和方法 | |
| SG11202110174PA (en) | Compositions and methods for the treatment of kras associated diseases or disorders | |
| TW201639962A (zh) | Ｒｎａ干擾劑 | |
| JP2024516183A5 (https=) | ||
| KR20020033744A (ko) | 사람 ｅｇ5의 발현을 억제하는 올리고뉴클레오티드 | |
| KR20200131263A (ko) | 변형 올리고뉴클레오티드 및 타우병증에서의 사용 방법 | |
| JP2022031642A (ja) | アンチセンスオリゴヌクレオチド | |
| TW202000199A (zh) | Irf4 表現之調節劑 | |
| JP7128517B2 (ja) | 副作用を減じたアンチセンス核酸 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP2007520474A (ja) | リボヌクレオチドレダクターゼｒ２に向けられたアンチセンスオリゴヌクレオチドおよび癌の処置のための併用療法におけるこの使用 | |
| CN119698475A (zh) | 血管紧张素原的高效rna靶向(arnatar) | |
| WO2023129939A2 (en) | Anti-sense oligonucleotides and uses thereof | |
| JPH1135595A (ja) | アンチセンスオリゴヌクレオチド及びそれを用いた制癌剤 | |
| JP2023526096A (ja) | Ｃａｒｄ９のスプライス調節のためのオリゴヌクレオチド | |
| WO2021002359A1 (ja) | 核酸医薬とその使用 | |
| US20250179497A1 (en) | Use of dinucleotide repeat rnas to treat cancer | |
| JP7707184B2 (ja) | 修飾短干渉ｒｎａ組成物、及びがんの処置におけるそれらの使用 | |
| US20250354144A1 (en) | Targeting muc1-c with a novel antisense oligonucleotide for the treatment of cancer | |
| JP2026505740A (ja) | Ｇｆｒａｌを標的にするアンチセンスオリゴマー及びこの用途 | |
| CN121204147A (zh) | 靶向rna修饰调控的方法 |